Carrolee Barlow - 02 Nov 2026 Form 4 Insider Report for Supernus, Inc. (INDV)

Reporting relationship: Director
Issuer ticker: INDV
Reported as of: 02 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2026, 18:04:15 UTC
Prior SEC filing: 25 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Filing notes and source

Key filing fact

Carrolee Barlow filed Form 4 for Supernus, Inc. (INDV) on 04 Nov 2026.

Key facts

This page summarizes Carrolee Barlow's Form 4 filing for Supernus, Inc. (INDV).
11 reported transactions and 10 derivative rows are listed below.
Accepted by SEC: 04 Nov 2026, 18:04.

Change

Previous filing in this sequence was filed on 25 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001745316 Primary reporting owner

Barlow Carrolee

Relationship: Director
Address: C/O SUPERNUS, INC., 9715 KEY WEST AVENUE, ROCKVILLE
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Signature date: 04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INDV transaction

Common Stock

Other

Transaction value
Shares: +41,652
Change %
Price: $0.000000^*
Shares after: 41,652
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +4,603
Change %
Price: $0.000000^*
Shares after: 4,603
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,603
Exercise price: $0.000000
Footnotes: F2, F3

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +15,729
Change %
Price: $0.000000^*
Shares after: 15,729
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,729
Exercise price: $37.76
Footnotes: F2

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +19,138
Change %
Price: $0.000000^*
Shares after: 19,138
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,138
Exercise price: $23.87
Footnotes: F2

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +14,330
Change %
Price: $0.000000^*
Shares after: 14,330
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,330
Exercise price: $15.58
Footnotes: F2

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +11,342
Change %
Price: $0.000000^*
Shares after: 11,342
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,342
Exercise price: $19.23
Footnotes: F2

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +10,545
Change %
Price: $0.000000^*
Shares after: 10,545
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,545
Exercise price: $20.91
Footnotes: F2

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +9,691
Change %
Price: $0.000000^*
Shares after: 9,691
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,691
Exercise price: $25.07
Footnotes: F2

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +12,708
Change %
Price: $0.000000^*
Shares after: 12,708
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,708
Exercise price: $18.15
Footnotes: F2

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +11,236
Change %
Price: $0.000000^*
Shares after: 11,236
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,236
Exercise price: $21.77
Footnotes: F2

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +7,665
Change %
Price: $0.000000^*
Shares after: 7,665
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,665
Exercise price: $32.60
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.

Footnote F2

Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except that performance stock unit awards were converted into time-vesting restricted stock units.

Footnote F3

These restricted stock units are settled in common stock upon vesting, which occurs on February 18, 2027.